Adimab, Mersana form antibody-drug conjugate alliance

Wednesday, August 1, 2012 01:49 PM

Adimab, a Lebanon, N.H.-based technology company focused on fully human therapeutic antibodies, and Mersana Therapeutics, a next-generation antibody-drug conjugate (ADC) company based in Cambridge, Mass., have joined forces to offer integrated antibody discovery and ADC technologies.

The alliance is built to offer pharmaceutical companies seamless access to Adimab's antibodies that have been specifically optimized for use in ADCs together with Mersana's Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads.

"We are excited to couple Mersana's innovative ADC technology with our platform for use by the pharmaceutical industry. The flexibility in payloads, linkers and drug loading enabled by Mersana's Fleximer technology complements Adimab's philosophy of tailoring drug development to the biology of the target of interest," said Tillman Gerngross, Adimab’s CEO. "With this deal, Adimab is further expanding its footprint beyond monoclonal antibody discovery. We view ADCs, as well as other aspects of antibody discovery such as bispecific formats, as important tools in the development of novel therapeutics."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs